Cambridge, UK and Indianapolis, US – 18 August 2020: Acacia Pharma Group plc (“Acacia Pharma” or the "Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that, further to the announcements on 13 August 2020 and 14 August 2020 regarding (i) the results of a placing of new ordinary shares in the Company (the "New Ordinary Shares") by means of an accelerated bookbuild offering (the “Placing”) and (ii) the publication of a prospectus in connection with the Placing (the “Prospectus”), 12,500,000 New Ordinary Shares have been admitted to trading on the regulated market of Euronext Brussels.
The New Ordinary Shares rank pari passu in all respects with the Company's existing ordinary shares in issue.
Following issue of the New Ordinary Shares, the Company's total issued share capital consists of 85,279,729 ordinary shares with one voting right per share. The Company does not hold any ordinary shares in treasury. Therefore the total number of voting rights in the Company is 85,279,729.
Contacts
Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, CFO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com
Citigate Dewe Rogerson (Financial PR)
Ze zijn vandaag om 0800 uur effectief op de markt gekomen.